Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.

作者信息

Poveda Eva, Rodés Berta, Toro Carlos, Martín-Carbonero Luz, Gonzalez-Lahoz Juan, Soriano Vincent

机构信息

Department of Infectious Diseases, Hospital Carlos Ill, Instituto de Salud Carlos Ill, Madrid, Spain.

出版信息

AIDS. 2002 Sep 27;16(14):1959-61. doi: 10.1097/00002030-200209270-00014.

DOI:10.1097/00002030-200209270-00014

PMID:12351957

Abstract

摘要

相似文献

[1]

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.

AIDS. 2002-9-27

[2]

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

AIDS Res Hum Retroviruses. 2002-7-1

[3]

Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.

J Med Virol. 2008-6

[4]

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.

J Antimicrob Chemother. 2008-9

[5]

Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.

AIDS. 2006-10-24

[6]

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

N Engl J Med. 2003-5-29

[7]

Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.

J Antimicrob Chemother. 2006-10

[8]

Functional characteristics of the natural polymorphisms of HIV-1 gp41 in HIV-1 isolates from enfuvirtide-naïve Korean patients.

Arch Virol. 2016-6

[9]

Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.

J Clin Virol. 2006-8

[10]

[HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].

Dtsch Med Wochenschr. 2003-5-9

引用本文的文献

[1]

The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.

Biomedicines. 2024-4-20

[2]

Detection and Prevention of Virus Infection.

Adv Exp Med Biol. 2022

[3]

Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.

J Virol. 2019-5-15

[4]

Current perspectives on HIV-1 antiretroviral drug resistance.

Viruses. 2014-10-24

[5]

Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Viruses. 2012-12

[6]

Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

J Biol Chem. 2012-1-10

[7]

Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency.

Biophys J. 2011-4-20

[8]

SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.

Antimicrob Agents Chemother. 2009-3

[9]

Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41.

Antiviral Res. 2008-10

[10]

Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant.

J Virol. 2008-8

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献